SITE002-0054

SITE002 (USA) › SITE002-0054

SITE002-0054

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2025-11-05

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 279); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-11 (study day 152); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 18); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.